Vioxx Rulings Could Bode Ill For N.J. Class Actions

Law360, New York (June 10, 2008, 12:00 AM EDT) -- In two recent Vioxx-related decisions, New Jersey appellate courts have further defined and reduced the scope of product liability actions by precluding: (1) medical monitoring in the absence of present injury, (2) consumer fraud claims, and (3) punitive damages.

In Sinclair v. Merck & Co. Inc., No. A-117-06 (N.J. June 4, 2008), the New Jersey Supreme Court affirmed the trial court's dismissal of a putative product liability class action seeking to recover the costs of medical monitoring of alleged silent or latent cardiovascular injury from ingestion...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.